ClinicalTrials.gg
Not yet recruitingNCT07600216Updated Oct 30, 2026

A Multicenter, Randomized Controlled Superiority Trial Comparing Robotic-Assisted Versus Expert Cognitive Fusion Prostate Biopsy in Obese Men

An interventional study of Robotic-Assisted Fusion Biopsy and Expert Cognitive Fusion Biopsy in Prostate Biopsy, sponsored by Shanghai East Hospital. Not yet recruiting at 1 site in China. Open to male participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Shanghai East Hospital · Not applicable, Interventional, and Diagnostic

Updated Oct 30, 2026First site in ChinaStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
570
Allocation
Randomized
Ages
40 Years and older
Sex
Male
01

Study summary

The trial aims to find out if using a robotic system to help perform prostate biopsies is better than having a highly experienced doctor perform the biopsy by hand in men with a high Body Mass Index (BMI).

While MRI-guided prostate biopsies are highly effective, carrying them out in men with obesity can be physically challenging for doctors. Extra pelvic tissue increases the depth the biopsy needle must travel and makes it difficult to manually hold the ultrasound probe perfectly steady. This physical difficulty might cause doctors to miss some aggressive prostate cancers.

This study tests whether a robotic arm-which completely locks the biopsy needle on target and eliminates human hand tremors-can improve cancer detection. The study will enroll up to 570 men with high BMI who have suspicious areas on their prostate MRI. Participants will be randomly assigned to receive either a robotic-assisted biopsy or a standard manual biopsy performed by an expert urologist.

To ensure the results are completely unbiased, participants will not know which method is being used on them. They will be placed behind a surgical drape and wear noise-canceling headphones playing music during the procedure to block out the sounds of the robotic motors. The main goal is to see if the robotic method safely and significantly increases the detection rate of clinically significant prostate cancer in this specific group of patients.

Read the detailed description

The integration of multiparametric magnetic resonance imaging (mpMRI) with transperineal targeted biopsy has established a new standard for prostate cancer diagnosis. However, clinical evidence, including findings from the previous IMAGINATION trial, suggests that the diagnostic accuracy of manual targeted biopsy techniques degrades in patients with high Body Mass Index (BMI). Deep perineal adiposity creates a "hostile anatomical environment" and a "fulcrum effect" that amplifies manual tremor.

The ROBUST (Robotic Optimization for Biopsy Under Substantial Tissue) trial is an investigator-initiated, multicentre, randomised, participant- and outcome-assessor-blinded superiority trial. It uses a frequentist group-sequential design to test whether robotic-assisted fusion biopsy is superior to expert cognitive fusion biopsy for participant-level detection of clinically significant prostate cancer (ISUP grade group ≥2) in men with obesity.

To isolate the impact of mechanical stabilization from operator inexperience, the control arm represents "peak human performance": operators must be credentialed experts with >500 total prostate biopsies, including >200 cognitive fusion targeted cases.

To reduce performance and detection bias, participants are blinded using a high surgical drape and noise-cancelling headphones; pathologists and data analysts remain blinded until database lock. Operating urologists cannot be blinded.

An independent DSMB will conduct formal interim analyses at approximately 25%, 50%, and 75% of maximum primary-outcome information (approximately 128, 256, and 384 evaluable participants), with the final analysis at 100% (approximately 510). A Lan-DeMets alpha-spending function with O'Brien-Fleming-type efficacy boundaries preserves the overall one-sided type I error rate at 0.025. Futility monitoring is non-binding and based on conditional power (threshold 20%). A prespecified Bayesian analysis of the primary estimand will be performed as a supportive analysis only and will not guide stopping decisions.

02

Conditions studied

  • Prostate Biopsy

Keywords

  • prostate biopsy
  • targeted biopsy
03

In context

Lead sponsor

Shanghai East Hospital is the lead sponsor of 95 studies on the registry; 50 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 40 years.
  • Serum PSA levels between 4 and 20 ng/ml and/or abnormal digital rectal examination (DRE).
  • High (BMI): defined as ≥ 28 kg/m ² for Asian cohorts and ≥ 30 kg/m ² for Non-Asian cohorts.
  • MRI-Positive: Presence of at least one suspicious lesion (PI-RADS score ≥ 3) on mpMRI.
  • Fitness for transperineal under local anaesthesia or conscious sedation.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment for prostate cancer.
  • History of major anorectal surgery preventing safe transperineal probe insertion.
  • to MRI.
  • Negative screening MRI (PI-RADS 1-2).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
570 participants (estimated)

Study arms

  • Experimental
    Robotic-Assisted Fusion Biopsy

    Robotic-Assisted Fusion Biopsy

    Procedure: Robotic-Assisted Fusion Biopsy

  • Active comparator
    Expert Cognitive Fusion Biopsy

    Expert Cognitive Fusion Biopsy

    Procedure: Expert Cognitive Fusion Biopsy

Interventions

  • ProcedureRobotic-Assisted Fusion Biopsy

    Participants in this arm will undergo a transperineal prostate biopsy utilizing a dedicated robotic fusion platform. The system features a mechanical arm or rigid fixator that completely locks the ultrasound probe and needle guide into a pre-planned coordinate trajectory. This mechanical stabilization uncouples the needle guide from manual human force, eliminating operator hand tremor and the "fulcrum effect" caused by deep pelvic adiposity. The urologist will obtain 3 to 4 targeted cores per MRI-visible lesion (PI-RADS ≥ 3) using the robotic interface, followed by a standard systematic biopsy. To prevent performance bias and placebo effects, participants will be blinded to the intervention using a high surgical drape and noise-canceling headphones.

  • ProcedureExpert Cognitive Fusion Biopsy

    Participants in this arm will undergo a standard manual transperineal prostate biopsy. To represent "peak human performance," the procedure will be performed exclusively by an expert urologist credentialed with a documented history of \>500 total prostate biopsies, including \>200 cognitive fusion targeted cases. The operator will mentally register the MRI lesion onto the real-time ultrasound image using anatomical landmarks, without the aid of any software overlay or robotic mechanical stabilization. The urologist will manually obtain 3 to 4 targeted cores per MRI-visible lesion (PI-RADS ≥ 3), followed by a standard systematic biopsy. To maintain the participant- and outcome-assessor-blinded, participants will be shielded by a surgical drape and wear noise-canceling headphones.

06

What researchers measure

Primary outcomes

  1. Detection Rate of Clinically Significant Prostate Cancer (csPCa) by Targeted Biopsy

    The primary efficacy endpoint is the proportion of participants in the intention-to-treat (ITT) population diagnosed with clinically significant prostate cancer (csPCa) specifically from the targeted biopsy cores. csPCa is strictly defined histopathologically as International Society of Urological Pathology (ISUP) Grade Group 2 or higher (Gleason score 3+4=7 or greater).

    Time frame: Up to 30 days post-procedure (at the time of final pathology report)

Secondary outcomes

  1. Detection Rate of Any Prostate Cancer by Targeted Biopsy

    The proportion of participants in whom any prostate cancer, defined as ISUP Grade Group 1 or higher (Gleason score 3+3=6 or greater), is detected specifically from the targeted biopsy cores.

    Time frame: Up to 30 days post-procedure

  2. Detection Rate of csPCa by Combined Biopsy

    The proportion of participants diagnosed with clinically significant prostate cancer (ISUP Grade Group 2 or higher) when combining the pathological results from both the targeted biopsy cores and the standard systematic biopsy cores.

    Time frame: Up to 30 days post-procedure

  3. Pathological Upgrade Rate

    The proportion of participants in whom the targeted biopsy cores detect a higher ISUP Grade Group of prostate cancer compared to the ISUP Grade Group detected by the background systematic biopsy cores in the same patient.

    Time frame: Up to 30 days post-procedure

  4. Incidence of Adverse Events (CTCAE v5.0)

    Incidence of adverse events graded according to CTCAE v5.0, including adverse events of special interest (gross haematuria requiring catheterisation/irrigation, urinary retention, febrile urinary tract infection, vasovagal syncope) and obesity-related complications (e.g., perineal haematoma).

    Time frame: Up to 30 days post-procedure

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) underlying the results reported in the primary publication, along with the study protocol and statistical analysis plan (SAP), will be made available to qualified scientific researchers. Data will be available beginning 6 months and ending 36 months following article publication. To gain access, researchers must submit a methodologically sound study proposal to the corresponding authors. Data sharing will be strictly subject to the execution of a formal data use agreement and must fully comply with local institutional review board (IRB) requirements and national data security regulations regarding cross-border data transfer.

Supporting information: Study protocol

Time frame: 1 year after publication

Access criteria: kuohaiandrew2000@vip.sina.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: start May 2026 → Jan 2027, primary completion May 2028 → Jan 2029 and completion May 2028 → Feb 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2026
First posted
May 20, 2026
StartEst.
Jan 1, 2027was May 2026
Primary completionEst.
Jan 1, 2029was May 2028
CompletionEst.
Feb 1, 2029was May 2028
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in China
Show site
  • Shanghai east hospital · Shanghai, China
Oct 30, 2026
Start date
May 30, 2026→Jan 1, 2027
Oct 30, 2026
Primary completion
May 30, 2028→Jan 1, 2029
Oct 30, 2026
Study completion
May 30, 2028→Feb 1, 2029
Oct 30, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • AddedIncidence of Adverse Events (CTCAE v5.0)Time frame: Up to 30 days post-procedure
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    1 site added — first site in China
    Show site
    • Shanghai east hospital · Shanghai, China
    Start date May 30, 2026→Jan 1, 2027
    Primary completion May 30, 2028→Jan 1, 2029
    Study completion May 30, 2028→Feb 1, 2029
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedIncidence of Adverse Events (CTCAE v5.0)Time frame: Up to 30 days post-procedure
    + 4 other changes: verification date, description, design details and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07600216
Lead sponsor
Shanghai East Hospital
Responsible party
Sponsor
First posted
May 20, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Jan 1, 2029 (estimated)
Completion
Feb 1, 2029 (estimated)
Last update
Oct 30, 2026

Study contacts

Qiang Li
Contact
liqressh@hotmail.com
+8613801602220
haifeng wang
Contact
kuohaiandrew2000@vip.sina.com
+8613681759891
haifeng wang
principal investigator · Shanghai East Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion